227 related articles for article (PubMed ID: 12716264)
1. Gepirone extended-release: new evidence for efficacy in the treatment of major depressive disorder.
Feiger AD; Heiser JF; Shrivastava RK; Weiss KJ; Smith WT; Sitsen JM; Gibertini M
J Clin Psychiatry; 2003 Mar; 64(3):243-9. PubMed ID: 12716264
[TBL] [Abstract][Full Text] [Related]
2. Gepirone extended-release treatment of anxious depression: evidence from a retrospective subgroup analysis in patients with major depressive disorder.
Alpert JE; Franznick DA; Hollander SB; Fava M
J Clin Psychiatry; 2004 Aug; 65(8):1069-75. PubMed ID: 15323591
[TBL] [Abstract][Full Text] [Related]
3. Sustained efficacy of gepirone-IR in major depressive disorder: a double-blind placebo substitution trial.
Amsterdam JD; Brunswick DJ; Gibertini M
J Psychiatr Res; 2004; 38(3):259-65. PubMed ID: 15003431
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
Spencer TJ; Wilens TE; Biederman J; Weisler RH; Read SC; Pratt R
Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
[TBL] [Abstract][Full Text] [Related]
5. A double-blind comparison of gepirone extended release, imipramine, and placebo in the treatment of outpatient major depression.
Feiger AD
Psychopharmacol Bull; 1996; 32(4):659-65. PubMed ID: 8993088
[TBL] [Abstract][Full Text] [Related]
6. A double-blind trial of low- and high-dose ranges of gepirone-ER compared with placebo in the treatment of depressed outpatients.
Wilcox CS; Ferguson JM; Dale JL; Heiser JF
Psychopharmacol Bull; 1996; 32(3):335-42. PubMed ID: 8961776
[TBL] [Abstract][Full Text] [Related]
7. Gepirone extended-release in the treatment of adult outpatients with major depressive disorder: a double-blind, randomized, placebo-controlled, parallel-group study.
Bielski RJ; Cunningham L; Horrigan JP; Londborg PD; Smith WT; Weiss K
J Clin Psychiatry; 2008 Apr; 69(4):571-7. PubMed ID: 18373383
[TBL] [Abstract][Full Text] [Related]
8. Paroxetine versus placebo: a double-blind comparison in depressed patients.
Claghorn JL; Kiev A; Rickels K; Smith WT; Dunbar GC
J Clin Psychiatry; 1992 Dec; 53(12):434-8. PubMed ID: 1487471
[TBL] [Abstract][Full Text] [Related]
9. Fluoxetine versus trazodone: efficacy and activating-sedating effects.
Beasley CM; Dornseif BE; Pultz JA; Bosomworth JC; Sayler ME
J Clin Psychiatry; 1991 Jul; 52(7):294-9. PubMed ID: 2071559
[TBL] [Abstract][Full Text] [Related]
10. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.
Detke MJ; Wiltse CG; Mallinckrodt CH; McNamara RK; Demitrack MA; Bitter I
Eur Neuropsychopharmacol; 2004 Dec; 14(6):457-70. PubMed ID: 15589385
[TBL] [Abstract][Full Text] [Related]
11. Buspirone in the management of major depression: a placebo-controlled comparison.
Fabre LF
J Clin Psychiatry; 1990 Sep; 51 Suppl():55-61. PubMed ID: 2211570
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of buspirone in generalized anxiety disorder with coexisting mild depressive symptoms.
Sramek JJ; Tansman M; Suri A; Hornig-Rohan M; Amsterdam JD; Stahl SM; Weisler RH; Cutler NR
J Clin Psychiatry; 1996 Jul; 57(7):287-91. PubMed ID: 8666569
[TBL] [Abstract][Full Text] [Related]
13. A 2-week, multicenter, randomized, double-blind, placebo-controlled, dose-ranging, phase III trial comparing the efficacy of oxymorphone extended release and placebo in adults with pain associated with osteoarthritis of the hip or knee.
Kivitz A; Ma C; Ahdieh H; Galer BS
Clin Ther; 2006 Mar; 28(3):352-64. PubMed ID: 16750450
[TBL] [Abstract][Full Text] [Related]
14. A randomized, double-blind comparison of duloxetine and venlafaxine in the treatment of patients with major depressive disorder.
Perahia DG; Pritchett YL; Kajdasz DK; Bauer M; Jain R; Russell JM; Walker DJ; Spencer KA; Froud DM; Raskin J; Thase ME
J Psychiatr Res; 2008 Jan; 42(1):22-34. PubMed ID: 17445831
[TBL] [Abstract][Full Text] [Related]
15. A double-blind comparison of Org 3770, amitriptyline, and placebo in major depression.
Bremner JD
J Clin Psychiatry; 1995 Nov; 56(11):519-25. PubMed ID: 7592505
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of mixed amphetamine salts extended release (adderall XR) in the management of oppositional defiant disorder with or without comorbid attention-deficit/hyperactivity disorder in school-aged children and adolescents: A 4-week, multicenter, randomized, double-blind, parallel-group, placebo-controlled, forced-dose-escalation study.
Spencer TJ; Abikoff HB; Connor DF; Biederman J; Pliszka SR; Boellner S; Read SC; Pratt R
Clin Ther; 2006 Mar; 28(3):402-18. PubMed ID: 16750455
[TBL] [Abstract][Full Text] [Related]
17. Relapse prevention with gepirone ER in outpatients with major depression.
Keller MB; Ruwe FJ; Janssens CJ; Sitsen JM; Jokinen R; Janczewski J
J Clin Psychopharmacol; 2005 Feb; 25(1):79-84. PubMed ID: 15643103
[TBL] [Abstract][Full Text] [Related]
18. Duloxetine for the treatment of major depressive disorder: safety and tolerability associated with dose escalation.
Wohlreich MM; Mallinckrodt CH; Prakash A; Watkin JG; Carter WP
Depress Anxiety; 2007; 24(1):41-52. PubMed ID: 16845641
[TBL] [Abstract][Full Text] [Related]
19. Deramciclane in the treatment of generalized anxiety disorder: a placebo-controlled, double-blind, dose-finding study.
Naukkarinen H; Raassina R; Penttinen J; Ahokas A; Jokinen R; Koponen H; Lepola U; Kanerva H; Lehtonen L; Pohjalainen T; Partanen A; Mäki-Ikola O; Rouru J;
Eur Neuropsychopharmacol; 2005 Dec; 15(6):617-23. PubMed ID: 15949921
[TBL] [Abstract][Full Text] [Related]
20. Duloxetine versus escitalopram and placebo: an 8-month, double-blind trial in patients with major depressive disorder.
Pigott TA; Prakash A; Arnold LM; Aaronson ST; Mallinckrodt CH; Wohlreich MM
Curr Med Res Opin; 2007 Jun; 23(6):1303-18. PubMed ID: 17559729
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
